Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
By S. Sakuramoto, M. Sasako, Toshiharu Yamaguchi, T. Kinoshitá, M. Fujii, A. Nashimoto, H. Furukawa, T. Nakajima, Y. Ohashi, H. Imamura and 4 more. New England Journal of Medicine, 2007
2,456 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/f0e31a6556cf2258162ade9deb10092aa9a65629
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) (2022, background): “As adjuvant chemotherapy, the efficacy of S-1 was proven in 2006 by the ACTS-GC trial [71, 72], a study that secured the place of postoperative S-1 monotherapy as a standard of care.”
- Japanese gastric cancer treatment guidelines 2014 (ver. 4) (2016, background): “Various regimens had been tested in numerous clinical trials in Japan without producing solid evidence in support of adjuvant chemotherapy until the efficacy of S-1 was proven in the ACTS-GC trial [29, 30], a study that secured the place of postoperative chemotherapy with S-1 as a standard of care (”
- Japanese gastric cancer treatment guidelines 2018 (5th edition) (2020, background): “Various regimens had been tested in numerous clinical trials in Japan without producing solid evidence in support of adjuvant chemotherapy until the efficacy of S-1 was proven in 2006 by the ACTSGC trial [62, 63], a study that secured the place of postoperative S-1 monotherapy as a standard of care ”
- Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. (2011, methodology): “Details of the patient demographics and baseline characteristics have been reported previously.(12) Fourteen patients in the S-1 group and 11 in the surgery-only group were ineligible, as shown in Figure 1.”
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, methodology): “The ACTS-GC trial evaluating adjuvant chemotherapy with S-1 following D2 resection in Asian patients demonstrated an OS benefit for patients treated with adjuvant chemotherapy [I, A] [48, 49].”